Biorasi plans to scale several aspects of its global CRO business following a PE investment – and while it does not plan to “buy size,” smaller strategic acquisitions are not out of the question, says company executive.
Stable 2019 predicted for pharma despite political and regulatory risk, finds credit agency
from in-PharmaTechnologist.com
Chinese firm plans ‘first-in-class’ biologics after $325m manufacturing investment
from BioPharma-Reporter.com
Hired and retired: Year’s end edition
from BioPharma-Reporter.com
Indivior succeeds in putting Suboxone generic on hold again
from in-PharmaTechnologist.com
M&A in the CRO industry: The Good, The Bad, and The Ugly
Consolidation
Infographic: Women in clinical research through the years
Patient centricity
Parexel and Eli Lilly team up to develop clinical researcher pool in China
Globalization
From mouse to man: New machine-learning model reduces number of ‘wasted experiments’
Clinical evolution
